Treatment patterns in non-small-cell lung cancer in USA: results of the CancerMPact Survey 2018

• Published in: Future oncology (London, England) Vol. 16; no. 7; pp. 255 - 262
• Main Authors: Robinson, David, Hawthorne, Stephanie, Zhao, Linda, Hanson, Madelyn, Kanas, Gena, Davis, Christine, Clark, Otavio
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-03-2020
• Subjects: Biomarkers; Cancer therapies; chemotherapy; Hematology; Histology; Hospitals; lung; Lung cancer; non-small-cell lung cancer; Oncology; Patients; patterns of care; Physicians; Polls & surveys; Questionnaires; Radiation therapy; Surgery; survey; United States > US; lung; patterns of care; survey; chemotherapy; non-small-cell lung cancer
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2019-0812

To report the results of a survey of USA physicians (CancerMPact) that treat non-small-cell lung cancer patients.
60 physicians were surveyed. Questions covered aspects of the treatment for all stages of the disease.
For stage I patients, over 70% of the treatments were based on surgery. For stage II/III disease, a strong preference for combined therapy (surgery/radiation/systemic therapy) was observed. For advanced/stage IV patients, physicians used systemic therapy alone, and choosed the regimen based on histology and biomarkers. Use of PD-L1 inhibitors was highly dependent on histology and biomarkers.
The treatment choices of non-small-cell lung cancer are increasingly complex, involve different treatment modalities and are highly dependent on histology and biomarkers, besides stage.